Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
This study is currently recruiting participants.
Verified June 2011
by National Cancer Institute (NCI)
Study NCT01085617 Information provided by National Cancer Institute (NCI)
First Received on March 11, 2010. Last Updated on June 21, 2011
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leukemia
Mucositis
Oral Complications
Additional conditions recognized in this trial
Leukemia, Lymphoid
Precursor Cell Lymphoblastic Leukemia-Lymphoma
More general conditions related to this trial
Digestive System Diseases
Gastroenteritis
Gastrointestinal Diseases
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Mouth Diseases
Neoplasms
Neoplasms by Histologic Type
Stomatognathic Diseases
Interventions listed in this trial
palifermin
rituximab
cyclophosphamide
cytarabine
daunorubicin hydrochloride
etoposide
fludarabine phosphate
imatinib mesylate
melphalan
mercaptopurine
methotrexate
nelarabine
pegaspargase
vincristine sulfate
assessment of therapy complications
total-body irradiation
Additional drug interventions recognized in this trial
6-Mercaptopurine
Daunorubicin
Fludarabine
Fludarabine monophosphate
Imatinib
Vidarabine
Vincristine
More general drug interventions related to this trial
Abortifacient Agents
Abortifacient Agents, Nonsteroidal
Alkylating Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antimetabolites
Antimetabolites, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Phytogenic
Antirheumatic Agents
Antiviral Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunologic Factors
Immunosuppressive Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Protein Kinase Inhibitors
Reproductive Control Agents
Therapeutic Uses
Tubulin Modulators
Sponsors listed in this trial
University College London Hospitals
Back to top of Main Content
